Markets open

Bristol-Myers Squibb Company

BMY · NYSE

Sep 2026upcoming

Next quarter

Consensus is $1.66 EPS for Sep 2026 across 9 estimates, ranging $1.59 to $1.74.

BMY Jun 2026

Reported Jul 30, 2026

Beat 28.30%

EPS estimate: $1.59
EPS actual: $2.04
Revenue estimate: —
Revenue actual: —
1-day move: +0.69%

Call highlights have not been generated for this quarter.

Symbol: BMY
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: NYSE

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve.

Key Issues

Bullish view

Second-quarter revenue rose 5% year over year to approximately $13 billion because newer products offset declines across the legacy portfolio. Management also highlighted growth-portfolio momentum, supporting the view that the company is transitioning successfully.

Bearish view

The same results confirm that the legacy portfolio is still shrinking, requiring newer medicines to replace established revenue. If growth products do not scale consistently, erosion in older therapies could limit overall performance.